EP0845987A4 - Inhibiteurs de la c-proteinase destines au traitement des affections liees a la surproduction de collagene - Google Patents

Inhibiteurs de la c-proteinase destines au traitement des affections liees a la surproduction de collagene

Info

Publication number
EP0845987A4
EP0845987A4 EP96930499A EP96930499A EP0845987A4 EP 0845987 A4 EP0845987 A4 EP 0845987A4 EP 96930499 A EP96930499 A EP 96930499A EP 96930499 A EP96930499 A EP 96930499A EP 0845987 A4 EP0845987 A4 EP 0845987A4
Authority
EP
European Patent Office
Prior art keywords
overproduction
collagen
treatment
disorders related
proteinase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96930499A
Other languages
German (de)
English (en)
Other versions
EP0845987A1 (fr
Inventor
Mitch Brenner
Wen-Bin Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen Inc
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of EP0845987A1 publication Critical patent/EP0845987A1/fr
Publication of EP0845987A4 publication Critical patent/EP0845987A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP96930499A 1995-08-08 1996-08-08 Inhibiteurs de la c-proteinase destines au traitement des affections liees a la surproduction de collagene Withdrawn EP0845987A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US203895P 1995-08-08 1995-08-08
US602038 1995-08-08
US60120396A 1996-02-14 1996-02-14
US601203 1996-02-14
US60918796A 1996-03-01 1996-03-01
US609187 1996-03-01
PCT/US1996/012876 WO1997005865A1 (fr) 1995-08-08 1996-08-08 Inhibiteurs de la c-proteinase destines au traitement des affections liees a la surproduction de collagene

Publications (2)

Publication Number Publication Date
EP0845987A1 EP0845987A1 (fr) 1998-06-10
EP0845987A4 true EP0845987A4 (fr) 2000-05-24

Family

ID=27357060

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96930499A Withdrawn EP0845987A4 (fr) 1995-08-08 1996-08-08 Inhibiteurs de la c-proteinase destines au traitement des affections liees a la surproduction de collagene

Country Status (9)

Country Link
EP (1) EP0845987A4 (fr)
JP (1) JPH11511137A (fr)
KR (1) KR19990036271A (fr)
CN (1) CN1198096A (fr)
AU (1) AU6951296A (fr)
BR (1) BR9609883A (fr)
CA (1) CA2229098A1 (fr)
MX (1) MX9801093A (fr)
WO (1) WO1997005865A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CN1198775A (zh) * 1995-08-08 1998-11-11 托马斯杰弗逊大学 重组c－蛋白酶及其加工、方法和用途
US5994351A (en) * 1998-07-27 1999-11-30 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
CN1230884A (zh) * 1996-07-22 1999-10-06 孟山都公司 硫羟砜金属蛋白酶抑制剂
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
SK21499A3 (en) * 1996-08-23 2000-05-16 Pfizer Arylsulfonylamino hydroxamic acid derivatives
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
US6037139A (en) * 1997-06-03 2000-03-14 Wisconsin Alumni Research Foundation System for assaying modulators of procollagen maturation
NZ502274A (en) 1997-07-22 2001-03-30 Shionogi & Co The use of a therapeutic or prophylactic agent containing a sulphonamide derivative for treating glomerulopathy
BR9810841A (pt) 1997-07-31 2001-07-10 Procter & Gamble Inibidores de metaloprotease alicìclicos
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
US6107337A (en) * 1998-08-06 2000-08-22 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
CA2352740A1 (fr) 1998-12-10 2000-06-15 F. Hoffmann-La Roche Ag Inhibiteurs de la c-proteinase de procollagene
US6492394B1 (en) 1998-12-22 2002-12-10 Syntex (U.S.A.) Llc Sulfonamide hydroxamates
TR200101868T2 (tr) * 1998-12-22 2001-11-21 F. Hoffmann-La Roche Ag Sülfonamit hidroksamatlar.
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
US6506936B1 (en) * 1999-02-25 2003-01-14 Fibrogen, Inc. N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
CZ20013155A3 (cs) 1999-03-03 2002-01-16 The Procter & Gamble Company Inhibitory metaloproteas
EP1165501A1 (fr) 1999-03-03 2002-01-02 The Procter & Gamble Company Inhibiteurs de metalloproteases, contenant alcenyle et alcynale
US6448278B2 (en) 1999-12-23 2002-09-10 Pfizer Inc. Procollagen C-proteinase inhibitors
US6462063B1 (en) 2000-02-04 2002-10-08 Fibrogen, Inc. C-proteinase inhibitors
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
AU2003221786A1 (en) 2002-04-25 2003-11-10 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
AU2003239599B8 (en) 2002-05-29 2008-08-14 Merck Sharp & Dohme Corp. Compounds useful in the treatment of anthrax and inhibiting lethal factor
US7105539B2 (en) 2002-12-03 2006-09-12 Enobia Pharma Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
CN1894202A (zh) 2003-12-19 2007-01-10 巴斯福股份公司 苯甲酰基取代的苯基丙氨酸酰胺
CA2566191A1 (fr) 2004-05-11 2005-12-15 Merck & Co., Inc. Procede de fabrication de derives d'acides amines n-sulfones
US8093236B2 (en) * 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2157982B1 (fr) 2007-05-04 2014-12-17 Marina Biotech, Inc. Lipides d'acides aminés et leurs utilisations
WO2009097893A1 (fr) * 2008-02-04 2009-08-13 Proyecto De Biomedicina Cima, S.L. Procédés de traitement d'une maladie cardiaque associée à une fibrose myocardique à l'aide d'un inhibiteur de pcp
CA3114240C (fr) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Derives d'imidazopyridine utilises en tant qu'inhibiteurs de l'integrine alpha4beta7
CA3115820A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Composes pour l'inhibition de l'integrine .alpha.4.beta.7
WO2020092375A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Dérivés de quinoléine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7
CN112969504B (zh) 2018-10-30 2024-04-09 吉利德科学公司 用于抑制α4β7整合素的化合物
CA3148613A1 (fr) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Composes derives de la phenylalanine et utilisation comme inhibiteurs del'integrine alpha-4 beta-7

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687841A (en) * 1985-10-18 1987-08-18 Monsanto Company Peptide hydroxamic acid derivatives
EP0262399A2 (fr) * 1986-08-29 1988-04-06 Takeda Chemical Industries, Ltd. Dérivés d'énols cycliques, préparation et utilisation
WO1991015507A1 (fr) * 1990-04-10 1991-10-17 Beecham Group Plc Phosphonopeptides inhibiteurs de collagenase
EP0606046A1 (fr) * 1993-01-06 1994-07-13 Ciba-Geigy Ag Arylsulfonamido-substitués dérivés d'acides hydroxamic

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US5292926A (en) * 1988-01-25 1994-03-08 Santen Pharmaceutical Co., Ltd. Cysteine derivatives
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
NZ229004A (en) * 1988-05-19 1993-09-27 Immunobiology Res Inst Inc Tetrapeptides having t cell helper acitivity
FR2655339B2 (fr) * 1989-04-19 1992-04-10 Medgenix Group Sa Composes et complexes utiles notamment en imagerie medicale.
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5114953A (en) * 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5443815A (en) * 1991-11-27 1995-08-22 Diatech, Inc. Technetium-99m labeled peptides for imaging
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
US5237057A (en) * 1992-04-06 1993-08-17 Biosite Diagnostics, Inc. Tetrahydrocannabinol derivatives and protein and polypeptide tetrahydrocannabinol derivative conjugates and labels
US5393902A (en) * 1994-04-26 1995-02-28 Lever Brothers Company, Division Of Conopco, Inc. Process for the preparation of bis(amidocarboxylic acids)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687841A (en) * 1985-10-18 1987-08-18 Monsanto Company Peptide hydroxamic acid derivatives
EP0262399A2 (fr) * 1986-08-29 1988-04-06 Takeda Chemical Industries, Ltd. Dérivés d'énols cycliques, préparation et utilisation
WO1991015507A1 (fr) * 1990-04-10 1991-10-17 Beecham Group Plc Phosphonopeptides inhibiteurs de collagenase
EP0606046A1 (fr) * 1993-01-06 1994-07-13 Ciba-Geigy Ag Arylsulfonamido-substitués dérivés d'acides hydroxamic

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AUST. J. CHEM. ( 1992 ), 45(2), 385-94, 1992 *
BRINGMANN, GERHARD ET AL: "Acetogenic isoquinoline alkaloids. 66. First total synthesis of korupensamines A and B", HETEROCYCLES ( 1994 ), 39(2), 503-8, 1994, XP000561812 *
CHEM. PHARM. BULL. ( 1990 ), 38(4), 1007-11, 1990 *
CHEMICAL ABSTRACTS, vol. 110, no. 23, 5 June 1989, Columbus, Ohio, US; abstract no. 205068, LELIEVRE, Y. ET AL: "Synovial collagenase inhibition by actinonin. Structure-activity relations" XP002134086 *
CHEMICAL ABSTRACTS, vol. 113, no. 17, 22 October 1990, Columbus, Ohio, US; abstract no. 147795, ODAKE, SHINJIRO ET AL: "Vertebrate collagenase inhibitor. I. Tripeptidyl hydroxamic acids" XP002134085 *
CHEMICAL ABSTRACTS, vol. 116, no. 17, 27 April 1992, Columbus, Ohio, US; abstract no. 174753, PERICH, JOHN W. ET AL: "Synthesis of casein-related peptides and phosphopeptides. XVI. The efficient synthesis of the casein-related O-phosphoseryl-containing peptide Ac-Glu-Ser(P)-Leu-Ser(P)-Ser(P)-Ser(P)-Glu-Glu-NHMe" XP002134088 *
CHEMICAL ABSTRACTS, vol. 123, no. 23, 4 December 1995, Columbus, Ohio, US; abstract no. 314466, OUCHI, T. ET AL: "Synthesis of polydepsipeptide with pendant carboxylic acid groups and its hydrolysis behavior" XP002134087 *
PATHOL. BIOL. ( 1989 ), 37(1), 43-6, 1989 *
See also references of WO9705865A1 *
STUD. POLYM. SCI. ( 1994 ), 12(BIODEGRADABLE PLASTICS AND POLYMERS), 528-33, 1994 *

Also Published As

Publication number Publication date
JPH11511137A (ja) 1999-09-28
AU6951296A (en) 1997-03-05
CA2229098A1 (fr) 1997-02-20
MX9801093A (es) 1998-04-30
EP0845987A1 (fr) 1998-06-10
CN1198096A (zh) 1998-11-04
KR19990036271A (ko) 1999-05-25
BR9609883A (pt) 1999-03-23
WO1997005865A1 (fr) 1997-02-20

Similar Documents

Publication Publication Date Title
EP0845987A4 (fr) Inhibiteurs de la c-proteinase destines au traitement des affections liees a la surproduction de collagene
EP0808103A4 (fr) Inhibiteurs de l'hydroxylation des proteines s'appliquant aux troubles fibroneoplasiques
PL327569A1 (en) Promedications of thrombosin inhibitors
IL121170A0 (en) Compositions for the treatment of dermatological disorders
HK1008331A1 (en) Process for synthesis of substituted sulphoxides
HK1089435A1 (en) Inhibitors of interleukin-1b converting enzyme
PL322549A1 (en) Inhibitors of proteinous farnesiltransferase
NO973009D0 (no) Fremgangsmåte for å inhibere kathepsin-k
NO961483L (no) Fremgangsmåte for behandling av oljeholdig formasjon
EP0805484A4 (fr) Procede de nettoyage de substrats
HUP9900110A3 (en) Novel process for the synthesis of omeprazole
FI956295A0 (fi) Menetelmä rasvapitoisten luonnontuotteiden fraktiointiin tai puhdistukseen
PL324034A1 (en) Tribenzimidazoles useful as inhibitors of topoisomerase i
IL112039A0 (en) Methods of inhibiting breast disorders
AU8636198A (en) Process for treatment of sulphates containing water
AU5198898A (en) Method for treatment of glutamate related disorders
ITMI950393A0 (it) Metodo per il trattamento di piante
HUP9904510A3 (en) Process for the synthesis of benzothiophenes
AU6460696A (en) Use of n-cyclohexyl benzamides for treating bowel disorders
HUP9900138A3 (en) Method for treatment of wood element
GB9510162D0 (en) Compositions for the treatment of skin conditions
AU1282099A (en) Method for treatment of disorders of attention
AU5117896A (en) Zap 70 inhibitors and methods for treatment of zap 70 signal transduction disorders
HUP9900923A3 (en) Process for the synthesis of vinyl-sulfenic acid derivatives
ZA9610134B (en) The use of 1-hydroxy-2-pyridones for the treatment of mucosal disorders which are difficult to treat

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980306

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/215 A, 7A 61K 31/38 B, 7A 61K 31/40 B, 7A 61K 31/66 B, 7A 61K 31/165 B, 7A 61K 31/70 B, 7A 61K 31/34 B, 7C 07C 259/06 B, 7C 07C 311/29 B, 7C 07D 207/48 B, 7C 07C 323/60 B, 7C 07K 5/02 B, 7C 07F 9/40 B

A4 Supplementary search report drawn up and despatched

Effective date: 20000411

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000301